This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of ...

Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

Lawmakers across the country are working through bills written to shield a growing source of revenue for hospital systems and ...

Nonprofit hospitals and health clinics are alarmed about a change that's coming to federal drug purchasing discounts next ...

Laws focused lowering drug prices have expanded in 15 states, with new boards and payment limits shaping affordability since 2017.

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

If drugmakers have their way, the federal government likely ends up spending $100 billion of taxpayer funds to bail out rural hospitals.

One reason libertarians don’t trust the government is because so many well-intentioned government programs end up either ...

Drugmaker AbbVie sued the state in June because of Senate Bill 71, which forbade drug companies from limiting how many ...